Homocysteine levels and amyotrophic lateral sclerosis: A possible link

References

• Mattson MP. Gene-diet interactions in brain ageing and neurodegenerative disorders. Ann Intern Med. 2003; 139: 441–4
   PubMed Web of Science ®Google Scholar
• Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases – guidelines and recommendations. Clin Chem Lab Med. 2003; 41: 1392–1403
   PubMed Web of Science ®Google Scholar
• Stanger O, Weger M, Renner W, Konetschny R. Vascular dysfunction in hyperhomocysteinaemia. Implications for atherothrombotic disease. Clin Chem Lab Med. 2001; 39: 725–33
   PubMed Web of Science ®Google Scholar
• Stanger O, Weger M. Interactions of homocysteine, nitric oxide, folate and radicals in the progressive damaged endothelium. Clin Chem Lab Med. 2003; 41: 1444–54
   PubMed Web of Science ®Google Scholar
• Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol. 2003; 2: 425–8
   PubMed Web of Science ®Google Scholar
• Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002; 346: 476–83
   PubMed Web of Science ®Google Scholar
• Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer's disease, and vascular dementia. Am J Clin Nutr. 2004; 80: 114–22
   PubMed Web of Science ®Google Scholar
• Quadri P, Fragiacomo C, Pezzati R, Zanda E, Tettamanti M, Lucca U. Homocysteine and B- vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med. 2005; 43: 1096–1100
   PubMed Web of Science ®Google Scholar
• Postuma RB, Lang A. Homocysteine and levodopa. Should Parkinson's disease patients receive preventative therapy?. Neurology. 2004; 63: 886–91
   PubMed Web of Science ®Google Scholar
• Robert K, Pagès C, Ledru A, Delabar J, Caboche J, Janel N. Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience. 2005; 133: 925–35
   PubMed Web of Science ®Google Scholar
• Kruman II, Culmsee C, Chan SL, Kruman Y, Guo Z, Penix L, Mattson MP. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000; 20: 6920–6
   PubMed Web of Science ®Google Scholar
• Vitvitsky V, Dayal S, Stabler S, Zhou Y, Wang H, Lentz SR, et al. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinaemia. Am J Physiol Regul Integr Comp Physiol. 2004; 287: 39–46
   Web of Science ®Google Scholar
• Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A. Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox Res. 2003; 5: 237–43
   PubMed Web of Science ®Google Scholar
• Obeid R, Herrmann W. Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett. 2006; 580: 2994–3005
   PubMed Web of Science ®Google Scholar
• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001; 344: 1688–1700
   PubMed Web of Science ®Google Scholar
• Sung JJ, Kim HJ, Choi-Kwon S, Lee J, Kim M, Lee KW. Homocysteine induces oxidative cytotoxicity in Cu/Zn superoxide dismutase mutant motor neuronal cell. Neuroreport. 2002; 13: 377–81
   PubMed Web of Science ®Google Scholar
• Chung YH, Hong JJ, Shin CM, Joo KM, Kim MJ, Cha CI. Immunohistochemical study on the distribution of homocysteine in the central nervous system of a transgenic mouse expressing a human Cu/Zn SOD mutation. Brain Research. 2003; 967: 226–34
   PubMed Web of Science ®Google Scholar
• Cho KJ, Chung YH, Shin C, Shin DH, Kim YS, Gurney ME, et al. Reactive astrocytes express p53 in the spinal cord of transgenic mice expressing a human Cu/Zn SOD mutation. Neuroreport. 1999; 10: 3939–43
   PubMed Web of Science ®Google Scholar
• Cho KJ, Chung YH, Joo KM, Lee YJ, Shin DH, Cha CI. Reactive astrocytes express PARP in the central nervous system of SOD-G93A transgenic mice. Brain Res. 2004; 1003: 199–204
   PubMed Web of Science ®Google Scholar
• Kim SH, Henkel JS, Beers DR, Sengun IS, Simpson EP, Goodman JC, et al. PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients. J Neuropathol Exp Neurol. 2003; 62: 88–103
   PubMed Web of Science ®Google Scholar
• Tjattas L, Ortiz DO, Dhivant S, Mitton K, Rogers E, Shea TB. Folate deficiency and homocysteine induce toxicity in cultured dorsal root ganglion neurons via cytosolic calcium accumulation. Aging Cell. 2004; 3: 71–6
   PubMed Web of Science ®Google Scholar
• Adalbert R, Engelhardt JI, Siklos L. DL-homocysteic acid application disrupts calcium homeostasis and induces degeneration of spinal motor neurons in vivo. Acta Neuropathol. 2002; 103: 428–36
   PubMed Web of Science ®Google Scholar
• Lee, KW, Park, JH, Kim, MY, Min, JH, Cho, AS, Hong, YH, , et al. Neuroprotective effects of multivitamin therapy in a transgenic mouse model of amyotrophic lateral sclerosis. Amyotroph Lat Scler. 2006;7(1)122–3, (abstract).
   Google Scholar
• Zhang X, Chen S, Li L, Wang Q, Le W. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1-G93A transgenic mice. Neuropharmacology. 2008; 54: 1112–9
   PubMed Web of Science ®Google Scholar
• Al-Chalaby A, Leigh PN. Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol. 2000; 13: 397–405
   PubMedGoogle Scholar
• Sazci, A, Idrisoglu, HA, Ergul, E, Akpinar, G. Methylenetetrahydrofolate reductase gene polymorphisms in amyotrophic lateral sclerosis (ALS). Amyotroph Lat Scler. 2005;6(1)86, (abstract).
   Google Scholar
• Zoccolella S, Simone IL, Samarelli V, Samarelli V, Tortelli R, Serlenga L, et al. Elevated plasma homocysteine levels in patients with ALS. Neurology. 2008; 70: 222–5
   PubMed Web of Science ®Google Scholar
• Kaji R, Kodama M, Imamura A, Hashida T, Kohara N, Ishizu M, et al. Effect of ultra-high- dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study. Muscle Nerve. 1998; 21: 1775–8
   PubMed Web of Science ®Google Scholar
• de Bree A, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary artery disease. Pharmacol Rev. 2002; 54: 599–618
   PubMed Web of Science ®Google Scholar
• Bendotti C, Tortarolo M, Suchak SK, Calvaresi N, Carvelli L, Bastone A, et al. Transgenic SOD1-G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem. 2001; 79: 737–46
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992; 326: 1464–8
   PubMed Web of Science ®Google Scholar
• Pehar M, Vargas MR, Cassina P, Barbeito AG, Beckman JS, Barbeito L. Complexity of astrocyte-motor neuron interactions in amyotrophic lateral sclerosis. Neurodegener Dis. 2005; 2: 139–46
   PubMed Web of Science ®Google Scholar
• Bedlack RS, Traynor BJ, Cudkowicz ME. Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotrophic lateral sclerosis. Expert Opin Emerg Drugs. 2007; 12: 229–52
   PubMed Web of Science ®Google Scholar
• Spalloni A, Geracitano R, Berretta N, Sgobio C, Bernardi G, Mercuri NB, et al. Molecular and synaptic changes in the hippocampus underlying superior spatial abilities in pre-symptomatic G93A + /+ mice overexpressing the human Cu/Zn superoxide dismutase (Gly93 --> ALA) mutation. Exp Neurol. 2006; 197: 505–14
   PubMed Web of Science ®Google Scholar
• Schreiber H, Gaigalat T, Wiedemuth-Catrinescu U, Graf M, Uttner I, Muche R, et al. Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis: a longitudinal study in 52 patients. J Neurol. 2005; 252: 772–81
   PubMed Web of Science ®Google Scholar
• Mezzapesa DM, Ceccarelli A, Dicuonzo F, Carella A, de Caro MF, Lopez M, et al. Whole-brain and regional brain atrophy in amyotrophic lateral sclerosis. AJNR Am J Neuroradiol. 2007; 28: 255–9
   PubMed Web of Science ®Google Scholar
• Siklos L, Engelhardt J, Harati Y, Smith RG, Joò F, Appel SH. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann Neurol. 1996; 39: 203–16
   PubMed Web of Science ®Google Scholar
• del Aguila MA, Longstreth WT, Jr, McGuire V, Koepsell TD, van Belle G. Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 2003; 60: 813–9
   PubMed Web of Science ®Google Scholar
• Izumi Y, Kaji R. Clinical trials of ultra-high-dose methylcobalamin in ALS. Brain Nerve. 2007; 59: 1141–7
   PubMedGoogle Scholar
• de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol. 2005; 57: 927–30
   PubMed Web of Science ®Google Scholar
• Perla-Kaján J, Twardowski T, Jakubowski H. Mechanisms of homocysteine toxicity in humans. Amino Acids. 2007; 32: 561–72
   PubMed Web of Science ®Google Scholar
• Schymick JC, Talbot K, Traynor BJ. Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet. 2007; 16: 233–42
   PubMed Web of Science ®Google Scholar
• Stanojlović, O, Rašić-Marković, A, Hrnčić, D, Sušić, V, Macut, D, Radosavljević, T, , et al. Two types of seizures in homocysteine thiolactone-treated adult rats, behavioral and electroencephalographic study. Cell Mol Neurobiol. 2008;29:329–339. DOI 10.1007/s10571-008-9324-8.
   PubMed Web of Science ®Google Scholar
• Diekstra FP, Beleza-Meireles A, Leigh NP, Shaw CE, Al-Chalabi A. Interaction between PON1 and population density in amyotrophic lateral sclerosis. Neuroreport. 2009; 20: 186–90
   PubMed Web of Science ®Google Scholar
• Valdmanis PN, Kabashi E, Dyck A, Hince P, Lee J, Dion P, et al. Association of paraoxonase gene cluster polymorphisms with ALS in France, Quebec, and Sweden. Neurology. 2008; 71: 514–20
   PubMed Web of Science ®Google Scholar
• Landers JE, Shi L, Cho TJ, Glass JD, Shaw CE, Leigh PN, et al. A common haplotype within the PON1 promoter region is associated with sporadic ALS. Amyotroph Lateral Scler. 2008; 9: 306–14
   PubMed Web of Science ®Google Scholar
• Wills AM, Landers JE, Zhang H, Richter RJ, Caraganis AJ, Cudkowicz ME, et al. Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS. Neurology. 2008; 70: 929–34
   PubMed Web of Science ®Google Scholar
• Cronin S, Greenway MJ, Prehn JH, Hardiman O. Paraoxonase promoter and intronic variants modify risk of sporadic amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2007; 78: 984–6
   PubMed Web of Science ®Google Scholar
• Slowik A, Tomik B, Wolkow PP, Partyka D, Turaj W, Malecki MT, et al. Paraoxonase gene polymorphisms and sporadic ALS. Neurology. 2006; 67: 766–70
   PubMed Web of Science ®Google Scholar
• Saeed M, Siddique N, Hung WY, Usacheva E, Liu E, Sufit RL, et al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology. 2006; 67: 771–6
   PubMed Web of Science ®Google Scholar
• Chiarugi A. Poly (ADP-ribose) polymerase: killer or conspirator? The ‘suicide hypothesis’ revisited. Trends Pharmacol Sci. 2002; 23: 122–9
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Frick B, Winkler C, Leblhuber F, Wirleitner B, Fuchs D. Hyperhomocysteinaemia and immune activation. Clin Chem Lab Med. 2003; 41: 1438–43
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Frick B, Wirleitner B, Schennach H, Fuchs D. Homocysteine accumulates in supernatants of stimulated human peripheral blood mononuclear cells. Clin Exp Immunol. 2003; 134: 53–6
   PubMed Web of Science ®Google Scholar
• Moisse K, Strong MJ. Innate immunity in amyotrophic lateral sclerosis. Biochim Byophys Acta. 2006; 1762: 1083–93
   PubMed Web of Science ®Google Scholar
• Moreau C, Devos D, Brunaud-Danel V, Defebvre L, Perez T, Destée A, et al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia?. Neurology. 2005; 65: 1958–60
   PubMed Web of Science ®Google Scholar
• Kamath AF, Chauhan AK, Kisucka J, Dole VS, Loscalzo J, Handy DE, et al. Elevated levels of homocysteine compromise blood-brain barrier integrity in mice. Blood. 2006; 107: 591–3
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Haller E, Kolomey I, Bennett SP, Potter H, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modelling ALS. PlosOne. 2007; 2: 1205
   PubMed Web of Science ®Google Scholar
• Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging. Am J Med. 2002; 113: 537–42
   PubMed Web of Science ®Google Scholar
• Soumarè A, Elbaz A, Ducros V, Tavernier B, Alpèrovitch A, Tzourio C. Cross-sectional association between homocysteine and motor function in the elderly. Neurology. 2006; 67: 985–90
   PubMed Web of Science ®Google Scholar
• Nilsson K, Gustafson L, Hultberg B. Elevated plasma homocysteine concentration in elderly patients with mental illness is mainly related to the presence of vascular disease and not the diagnosis. Dement Geriatr Cogn Disord. 2007; 24: 162–8
   PubMed Web of Science ®Google Scholar
• Irizarry MC, Gurol ME, Raju S, Diaz-Arrastia R, Locascio JJ, Tennis M, et al. Association of homocysteine with plasma amyloid beta protein in ageing and neurodegenerative disease. Neurology. 2005; 65: 1402–8
   PubMed Web of Science ®Google Scholar